1. Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women.
- Author
-
Cressey TR, Van Dyke R, Jourdain G, Puthanakit T, Roongpisuthipong A, Achalapong J, Yuthavisuthi P, Prommas S, Chotivanich N, Maupin R, Smith E, Shapiro DE, and Mirochnick M
- Subjects
- Adolescent, Adult, Area Under Curve, Drug Therapy, Combination, Female, HIV Infections virology, HIV Protease Inhibitors administration & dosage, HIV Protease Inhibitors therapeutic use, HIV-1 drug effects, Humans, Lopinavir, Pregnancy, Pregnancy Complications, Infectious virology, Pregnancy Trimester, Third, Pyrimidinones administration & dosage, Pyrimidinones therapeutic use, Ritonavir pharmacokinetics, Thailand, Treatment Outcome, Young Adult, HIV Infections drug therapy, HIV Protease Inhibitors pharmacokinetics, Postpartum Period, Pregnancy Complications, Infectious drug therapy, Pyrimidinones pharmacokinetics
- Abstract
Lopinavir (LPV) exposure is reduced during the third trimester of pregnancy. We report the pharmacokinetics of standard LPV-ritonavir dosing (400/100 mg twice daily) in the immediate and early postpartum period when initiated during labor. In 16 human immunodeficiency virus-infected Thai women, the median (range) LPV area under the concentration-time curve and maximum and minimum concentrations in plasma were 99.7 (66.1 to 180.5) microg x h/ml, 11.2 (8.0 to 17.5) microg/ml, and 4.6 (1.7 to 12.5) microg/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported.
- Published
- 2009
- Full Text
- View/download PDF